Claims
- 1. The use of a compound of formula (3) to prepare a medicament for the treatment of conditions mediated by p38α kinase, wherein the compound of formula (3) is of the formula:
- 2. The use of claim 1 wherein X1 is CO and X2 is CH2.
- 3. The use of claim 1 or 2 wherein said furanyl ring system is optionally substituted by one substituent selected from the group consisting of alkyl, alkoxy, cycloalkyl, cycloheteroalkyl, heteroaryl, halogen, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, acyl, carboxy, hydroxy, aminocarbonyl, arylcarbonyl, heteroarylcarbonyl, CF3, cyano, amino and alkylamino.
- 4. The use of any of claims 1-3 wherein Ph is optionally substituted by one substituent selected from the group consisting of alkyl, alkoxy, cycloalkyl, cycloheteroalkyl, heteroaryl, halogen, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, acyl, carboxy, hydroxy, aminocarbonyl, arylcarbonyl, heteroarylcarbonyl, CF3, cyano, amino, alkylamino and aryl.
- 5. The use of a compound of formula (3) to prepare a medicament for treating conditions mediated by p38% kinase wherein the compound of formula (3) is of the formula:
- 6. The use of claim 5 wherein X1 is CO and X2 is CH2.
- 7. The use of claim 5 or 6 wherein said thiophene ring system is optionally substituted by at least one substituent selected from the group consisting of alkyl, alkoxy, cycloalkyl, cycloheteroalkyl, heteroaryl, halogen, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, acyl, carboxy, hydroxy, aminocarbonyl, arylcarbonyl, heteroarylcarbonyl, CF3, cyano, amino, alkylamino, and aryl.
- 8. The use of any of claims 5-7 wherein Ph is optionally substituted by one substituent selected from the group consisting of alkyl, alkoxy, cycloalkyl, cycloheteroalkyl, heteroaryl, halogen, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, acyl, carboxy, hydroxy, aminocarbonyl, arylcarbonyl, heteroarylcarbonyl, CF3, cyano, amino, alkylamino and aryl.
- 9. The use of a compound of formula (3) to prepare a medicament for the treatment of conditions mediated by p38α kinase wherein the compound of formula (3) is of the formula:
- 10. The use of claim 9 wherein X1 is CO and X2 is CH2.
- 11. The use of claim 9 or 10 wherein Ar1 is optionally substituted by at least one substituent selected from the group consisting of alkyl, alkoxy, cycloalkyl, cycloheteroalkyl, heteroaryl, halogen, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, acyl, carboxy, hydroxy, aminocarbonyl, arylcarbonyl, heteroarylcarbonyl, CF3, cyano, amino, alkylamino, and aryl.
- 12. The use of any of claims 9-11 wherein Ph is optionally substituted by one substituent selected from the group consisting of alkyl, alkoxy, cycloalkyl, cycloheteroalkyl, heteroaryl, halogen, alkylaminocarbonyl, arylaminocarbonyl, heteroarylaminocarbonyl, acyl, carboxy, hydroxy, aminocarbonyl, arylcarbonyl, heteroarylcarbonyl, CF3, cyano, amino, alkylamino and aryl.
- 13. The use of a compound of formula (3) to prepare a medicament for the treatment of conditions mediated by p38α kinase wherein the compound of formula (3) is a compound illustrated in FIGS. 1A-1I.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation-in-part of U.S. application Ser. No. 09/385,494, filed Aug. 27, 1999, the contents of which are incorporated herein by reference. This application claims priority under 35 U.S.C. § 119(e) to provisional application Ser. No. 60/185,571 filed Feb. 28, 2000, the contents of which are incorporated herein by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60185571 |
Feb 2000 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09385494 |
Aug 1999 |
US |
Child |
09796997 |
Feb 2001 |
US |